KCa3.1 Blockers Inhibit Cell Proliferation in Chronic Lymphocytic Leukemia

Groessinger, EM; Weiss, L; Hinterseer, E; Schmoelzer, J; Oberascher, K; Asslaber, A; Egle, A; Hartmann, TN; Greil, R; Kerschbaum, HH Blood (ASH Annual Meeting Abstracts) 2012. 2012. #3887:

Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.

Auberger, J; Lass-Flörl, C; Aigner, M; Clausen, J; Gastl, G; Nachbaur, D; J Antimicrob Chemother. 2012; 67(9):2268-2273

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkinxxxs lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Engert, A; Haverkamp, H; Kobe, C; Markova, J; Renner, C; Ho, A; Zijlstra, J; Kral, Z; Fuchs, M; Hallek, M; Kanz, L; Dohner, H; Dorken, B; Engel, N; Topp, M; Klutmann, S; Amthauer, H; Bockisch, A; Kluge, R; Kratochwil, C; Schober, O; Greil, R; Andreesen, R; Kneba, M; Pfreundschuh, M; Stein, H; Eich, HT; Muller, RP; Dietlein, M; Borchmann, P; Diehl, V LANCET. 2012; 379(9828): 1791-1799.

Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target

Johrer, K; Obkircher, M; Neureiter, D; Parteli, J; Zelle-Rieser, C; Maizner, E; Kern, J; Hermann, M; Hamacher, F; Merkel, O; Wacht, N; Zidorn, C; Scheideler, M; Greil, R J MOL MED. 2012; 90(6): 681-693.

Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Tausch, C; Taucher, S; Dubsky, P; Seifert, M; Reitsamer, R; Kwasny, W; Jakesz, R; Fitzal, F; Filipcic, L; Fridrik, M; Greil, R; Gnant, M ANN SURG ONCOL. 2012; 19(6): 1808-1817.

Dose-Intensification in Early Unfavorable Hodgkinxxxs Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

von Tresckow, B; Plutschow, A; Fuchs, M; Klimm, B; Markova, J; Lohri, A; Kral, Z; Greil, R; Topp, MS; Meissner, J; Zijlstra, JM; Soekler, M; Stein, H; Eich, HT; Mueller, RP; Diehl, V; Borchmann, P; Engert, A J CLIN ONCOL. 2012; 30(9): 907-913.

Tissue-Sparing Application of the Newly Proposed IASLC/ATS/ERS Classification of Adenocarcinoma of the Lung Shows Practical Diagnostic and Prognostic Impact

Sterlacci, W; Savic, S; Schmid, T; Oberaigner, W; Auberger, J; Fiegl, M; Tzankov, A AM J CLIN PATHOL. 2012; 137(6): 946-956.

Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment.

Horejs-Hoeck, J; Schwarz, H; Lamprecht, S; Maier, E; Hainzl, S; Schmittner, M; Posselt, G; Stoecklinger, A; Hawranek, T; Duschl, A; J IMMUNOL. 2012; 188(11): 5319-5326.

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

Reinacher-Schick, A; Schulmann, K; Modest, DP; Bruns, N; Graeven, U; Jaworska, M; Greil, R; Porschen, R; Arnold, D; Schmiegel, W; Tannapfel, A BMC CANCER. 2012; 12: 349

Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers

Rick, FG; Buchholz, S; Schally, AV; Szalontay, L; Krishan, A; Datz, C; Stadlmayr, A; Aigner, E; Perez, R; Seitz, S; Block, NL; Hohla, F CELL CYCLE. 2012; 11(13): 2518-2525.